EW · NYSE · STOCK
Edwards Lifesciences (EW) Stock Analysis
$86.32
52W $72.40 – $96.29
56/100
$49.10B
49.0
0.86
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is EW Bullish or Bearish?
Bullish.
Innellis AI committee rates Edwards Lifesciences (EW) Buy with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.54 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.46 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 49.1 is expensive by classic value standards — Value
- Price-to-book of 4.8x prices in significant intangible value — Value
- EPS declining -75.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 59%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 49.1 is expensive by classic value standards
Growth Analyst
bearish
40
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -75.2% YoY despite any revenue growth
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 57.6 to 56.5.
- Committee agreement increased notably from 33% to 50%.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: News Analyst.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: stance neutral->bullish.
- Portfolio Manager: score 30->35 (+5).
- Technical Analyst: score 48->54 (+5); +1 bullish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
52.2
Neutral
MACD Histogram
0.059
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$85.58
Resistance
$86.98
Bollinger %B
0.48
Inside Bands
Price vs Moving Averages
EMA 9
$85.93
Above
EMA 21
$86.49
Below
EMA 50
$87.33
Below
EMA 200
$85.39
Above
Fundamental Analysis
Valuation
51
Growth
60
Profitability
77
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
49.0×
P/B Ratio
4.63×
PEG Ratio
-0.65
Dividend Yield
0.00%
52W High
$96.29
52W Low
$72.40
Quality & Growth
ROE
1038.4%
ROA
783.7%
Gross Margin
7798.0%
Operating Margin
2809.4%
Revenue Growth YoY
—
Debt / Equity
0.07
AI Fundamental Assessment
P/E ratio of 49.0 (rich relative to a 15-40x range); Price-to-book of 4.6x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.4%; Return on assets of 7.8%; Net margin of 15.4%; Gross margin of 78.0%; Current ratio of 4.52 (healthy short-term liquidity); Debt-to-equity of 0.07; Free cash flow per share is positive (2.49); Most recent quarter beat estimates by 2.3%; 2 consecutive earnings beats; EPS growth decelerating (+34.5% -> +0.0% QoQ); Average YoY EPS growth of 16.4%; Analyst estimates rising over recent quarters
Get the Full EW Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →